Novo Nordisk (NVO) and Eli Lilly (LLY) manufacture the top three weight loss drugs on the market, but heightened demand is ...

Novo Nordisk (NVO) reported better than expected sales for its weight loss therapy Wegovy with its Q3 2024 financials on ...

CEO David Ricks said the sale of cheaper, off-brand versions of the company’s blockbuster weight loss drug isn’t having a ...

Viking Therapeutics shares rose Monday morning before reversing course and declining after reporting the latest results from ...

Surging demand for weight loss drugs Wegovy and Zepbound from Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) has fueled concerns over a significant risk linked to the popular drug class: loss of ...

Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and ...

Eli Lilly (LLY) is considering testing its blockbuster weight-loss drugs in individuals who are not yet overweight but are at risk of weight gain, according to an exclusive Financial Times report.

Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...

The massive success of glucagon-like peptide-1 (GLP-1) agonist drugs sold by Eli Lilly LLY and Novo Nordisk has ... with GLP-1s to possibly enhance weight loss or simply offer an alternative ...

Eli Lilly ( LLY) is planning to advertise its blockbuster weight loss drug, Zepbound, for the first time next month. Despite ...

Helped in part by the hype around weight-loss drugs, both NVO and LLY have outperformed the overall S&P 500 for most of the past year. However, NVO has suffered a setback lately and recently fell ...

Eli Lilly (LLY) stock is soaring Thursday after the ... driven by demand for its weight-loss drugs, Mounjaro and Zepbound, as well as its breast cancer drug Verzenio. Its earnings per share ...